ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2203

Changes in Tophus Composition During Urate-Lowering Therapy: A Dual Energy CT Study

Leanne Chen1, Gregory Gamble1, Anne Horne1, Jill Drake2, Anthony Doyle1, Till Uhlig3, Lisa Stamp2 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, New Zealand, 3Diakonhjemmet Hospital, Oslo, Norway

Meeting: ACR Convergence 2022

Keywords: Computed tomography (CT), gout, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Imaging of Rheumatic Diseases

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: The gouty tophus is an organized structure composed of monosodium urate (MSU) crystals and chronic inflammatory soft tissue. Long-term urate-lowering therapy leads to gradual reduction in the size of tophi. However, it is unknown whether the composition of the tophus changes during urate-lowering therapy. Conventional computed tomography (CT) allows measurement of tophus volume in a reliable and reproducible manner. In addition to conventional CT properties, dual energy computed tomography (DECT) allows measurement of MSU crystals within tophi. The aim of this DECT study was to determine whether the composition of the tophus changes over time during urate-lowering therapy.

Methods: Serial DECT scans from 32 people with gout were obtained during a two-year study of allopurinol dosing. All participants received allopurinol dose-escalation, achieved the target SU during the study (< 6 mg/dL) and had evidence of DECT urate deposition within tophi at baseline. DECT scans of the feet and ankles were obtained at baseline, Year 1 and Year 2. Up to five index tophi were selected from each patient, with 103 separate tophi included in the analysis. Using manual outlining methods of conventional CT (CT) and DECT scans, the same index tophi were serially measured for total tophus volume and urate volume. For each tophus, the soft tissue volume was then calculated by subtracting the urate volume from the total tophus volume. Data were analyzed using general estimating equations (GEE) mixed models with analysis of covariance (ANCOVA).

Results: In response to allopurinol dose escalation, the mean (SD) serum urate reduced from 7.2 (0.5) mg/dL at baseline to 5.2 (0.3) mg/dL at Year 2. Within the analyzed tophi, the total tophus volume reduced over the two-year period; from mean (SD) 5.17 (5.55) cm3 to 2.61 (2.73) cm3, P< 0.001. Both the tophus urate volumes and tophus soft tissue volumes reduced over time (P< 0.001), but greater reductions in tophus urate volumes were observed (Figures 1 and 2). Overall, the tophus urate volume decreased by 70.6 [62.8, 78.4]%, and tophus soft tissue volume decreased by 37.8% [31.4, 44.1]%. The tophus urate:soft tissue ratio reduced from 0.15 [0.12, 0.19] at baseline to 0.05 [0.02, 0.09] at Year 2.

Conclusion: This dual energy CT study demonstrates that the composition of the tophus changes during urate-lowering therapy for gout management. While both urate and soft tissue volumes reduce over time, the chronic inflammatory soft tissue within the tophus is slower to respond than the MSU crystals.

Supporting image 1

Figure 1. Example of an individual tophus measurement and change in the tophus composition over time

Supporting image 2

Figure 2. Comparison of change in urate and soft tissue volumes within all analyzed tophi. A. Percentage change from baseline in urate volume and soft tissue volume; B. Urate volume: soft tissue volume ratio over time. Data are presented as mean (95% CI).


Disclosures: L. Chen, None; G. Gamble, None; A. Horne, None; J. Drake, None; A. Doyle, None; T. Uhlig, None; L. Stamp, None; N. Dalbeth, AstraZeneca, Dyve Biosciences, Horizon, Selecta, JW Pharmaceutical Corporation, PK Med, PTC Therapeutics, Protalix.

To cite this abstract in AMA style:

Chen L, Gamble G, Horne A, Drake J, Doyle A, Uhlig T, Stamp L, Dalbeth N. Changes in Tophus Composition During Urate-Lowering Therapy: A Dual Energy CT Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/changes-in-tophus-composition-during-urate-lowering-therapy-a-dual-energy-ct-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-tophus-composition-during-urate-lowering-therapy-a-dual-energy-ct-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology